Search research articles
Contact Us
Filters
Showing results (201-210 of 337) with videos related to
Page
of 34
Sort By:
Journal of Cancer Research and Clinical Oncology
|
September 26, 2023
Principles of oncology taught in a one-week course
Matthias Oettle, Marcel Büttner, Marie Forster, et al.
Blood
|
July 9, 2004
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group
Georg Lenz, Martin Dreyling, Eva Schiegnitz, et al.
Haematologica
|
June 3, 2008
Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma
Inga Nieländer, José I Martín-Subero, Florian Wagner, et al.
Annals of Hematology
|
March 8, 2024
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, et al.
Hemasphere
|
February 20, 2020
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
Wendy B C Stevens, Katerina Bakunina, Marloes Cuijpers, et al.
Transplantation
|
January 1, 2008
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab
Ralf U Trappe, Sylvain Choquet, Petra Reinke, et al.
Haematologica
|
March 17, 2018
Impact of age on genetics and treatment efficacy in follicular lymphoma
Stefan Alig, Vindi Jurinovic, Alessandro Pastore, et al.
Haematologica
|
December 18, 2012
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas
Agnieszka Korfel, Thomas Elter, Eckhard Thiel, et al.
Leukemia & Lymphoma
|
July 16, 2010
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference
Martin Dreyling, Eva Hoster, Silvia Bea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2005
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Georg Lenz, Martin Dreyling, Eva Hoster, et al.
Page
of 34
Search research articles
Search
Showing results (201-210 of 337) with videos related to
Sort By:
Page
of 34
Journal of Cancer Research and Clinical Oncology
|
September 26, 2023
Principles of oncology taught in a one-week course
Matthias Oettle, Marcel Büttner, Marie Forster, et al.
Blood
|
July 9, 2004
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group
Georg Lenz, Martin Dreyling, Eva Schiegnitz, et al.
Haematologica
|
June 3, 2008
Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma
Inga Nieländer, José I Martín-Subero, Florian Wagner, et al.
Annals of Hematology
|
March 8, 2024
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, et al.
Hemasphere
|
February 20, 2020
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
Wendy B C Stevens, Katerina Bakunina, Marloes Cuijpers, et al.
Transplantation
|
January 1, 2008
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab
Ralf U Trappe, Sylvain Choquet, Petra Reinke, et al.
Haematologica
|
March 17, 2018
Impact of age on genetics and treatment efficacy in follicular lymphoma
Stefan Alig, Vindi Jurinovic, Alessandro Pastore, et al.
Haematologica
|
December 18, 2012
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas
Agnieszka Korfel, Thomas Elter, Eckhard Thiel, et al.
Leukemia & Lymphoma
|
July 16, 2010
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference
Martin Dreyling, Eva Hoster, Silvia Bea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2005
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Georg Lenz, Martin Dreyling, Eva Hoster, et al.
Page
of 34